210 related articles for article (PubMed ID: 12620173)
1. What are the risks of long-term NSAIDs and COX-2 inhibitors?
DeBisschop M
J Fam Pract; 2003 Mar; 52(3):199-200. PubMed ID: 12620173
[TBL] [Abstract][Full Text] [Related]
2. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
3. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
5. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
7. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
Pascucci RA
J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
9. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
Bjarnason I
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S27-36. PubMed ID: 10379467
[TBL] [Abstract][Full Text] [Related]
10. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
12. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
Hochberg MC
Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
[TBL] [Abstract][Full Text] [Related]
13. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
14. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
15. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E
Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602
[No Abstract] [Full Text] [Related]
16. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
[TBL] [Abstract][Full Text] [Related]
17. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
18. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors.
Rabeneck L
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii32-9. PubMed ID: 14585916
[TBL] [Abstract][Full Text] [Related]
19. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
20. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
